Journal
LABORATORY INVESTIGATION
Volume 94, Issue 9, Pages 978-990Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/labinvest.2014.91
Keywords
-
Categories
Funding
- Research Grants Council of Hong Kong [CUHK05/CRF/09]
- Chinese University of Hong Kong
- Key Program of the National Natural Science Foundation of China [81130012]
Ask authors/readers for more resources
TGF-beta/Smad3 signaling plays a pivotal role in the pathogenesis of peritoneal fibrosis associated with peritoneal dialysis (PD). MicroRNA-29 (miR-29) is known as a potent downstream inhibitor of TGF-beta/Smad3 in renal fibrosis. In this study, we examined the therapeutic potential for nniR-29b on PD-related peritoneal fibrosis in a mouse model of PD induced by daily infusion of 4.25% dextrose-containing PD fluid (PDF). MiR-29b-expressing plasnnid was delivered into the peritoneum via an ultrasound-microbubble-mediated system before and at day 14 after PDF. We found that mice on PD developed peritoneal fibrosis with impaired peritoneal function, which was associated with a loss of miR-29b. In contrast, overexpression of miR-29b before the PDF infusion showed a protective effect on peritoneal fibrosis including EMT and prevented peritoneal dysfunction. Moreover, delayed miR-29b treatment until peritoneal fibrosis was established at day 14 also halted the progression of peritoneal fibrosis at day 28. Further studies identified that blockade of the Sp1-TGF-beta/Smad3 pathway may be a mechanism by which miR-29b inhibited peritoneal fibrosis. In conclusion, treatment with miR-29b may represent a novel and effective therapy for PD-associated peritoneal fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available